A strategy to reduce unnecessary prostate biopsies in patients with tPSA >10 ng ml−1 and PI-RADS 1–3
Asian Journal of Andrology · 2025
DOI: 10.4103/aja202499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Andrology, 2025. Verfasst von Qi-Fei Dong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Prostate, Unnecessary Procedures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
We propose a strategy to reduce unnecessary prostate biopsies in Chinese patients with total prostate-specific antigen (tPSA) >10 ng ml −1 and Prostate Imaging Reporting and Data System (PI-RADS) scores between 1 and 3. Clinical data derived from 517 patients of The First Affiliated Hospital of USTC (Hefei, China) from January 2020 to December 2023 who met the screening criteria for the study were retrospectively collected. Independent predictors were identified via univariate and multivariate logistic regression analysis. The diagnostic capacity of clinical variables was evaluated using the receiver operating characteristic (ROC) curves and area under the curve (AUC). A prostate biopsy strategy was developed via risk stratification. Of the 517 patients, 17/348 (4.9%) with PI-RADS 1–2 were diagnosed with clinically significant prostate cancer (csPCa), and 27/169 (16.0%) patients with PI-RADS 3 were diagnosed with csPCa. The appropriate prostate-specific antigen density (PSAD) cut-off values were 0.45 ng ml −2 for PI-RADS 1–2 patients and 0.3 ng ml −2 for PI-RADS 3 patients. The appropriate prostate volume (PV) cut-off values were 40 ml for PI-RADS 1–2 patients and 50 ml for PI-RADS 3 patients. The prostate biopsy strategy based on PSAD and PV developed in this study can reduce unnecessary prostate biopsies in patients with tPSA >10 ng ml −1 and PI-RADS 1–3. In the study, 66.5% (344/517) patients did not need to undergo prostate biopsy, at the expense of missing only 1.7% (6/344) patients with csPCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
- Department of Urology, Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China.
Zitieren
APA
Dong, Q. F., Liu, Y. X., Chen, Y. H., Ma, Y. F., Zhou, T., Fan, X. F., Yu, X., Wang, C. M., & Xiao, J. (2025). A strategy to reduce unnecessary prostate biopsies in patients with tPSA >10 ng ml−1 and PI-RADS 1–3. Asian Journal of Andrology. https://doi.org/10.4103/aja202499
Vancouver
Dong QF, Liu YX, Chen YH, Ma YF, Zhou T, Fan XF, et al. A strategy to reduce unnecessary prostate biopsies in patients with tPSA >10 ng ml−1 and PI-RADS 1–3. Asian Journal of Andrology. 2025. doi:10.4103/aja202499
BibTeX
@article{Dong2025,
author = {Dong, Qi-Fei and Liu, Yi-Xun and Chen, Yu-Han and Ma, Yi-Fan and Zhou, Tao and Fan, Xue-Feng and Yu, Xiang and Wang, Chang-Ming and Xiao, Jun},
title = {A strategy to reduce unnecessary prostate biopsies in patients with tPSA >10 ng ml−1 and PI-RADS 1–3},
journal = {Asian Journal of Andrology},
year = {2025},
doi = {10.4103/aja202499}
}
EUVIMED